title: Spanish Menopause Society position statement: Use of denosumab in postmenopausal women.
abstract: Denosumab is a new drug developed for the treatment of osteoporosis. Moreover, increasing evidences link denosumab with benefits in cancer, an area of interest for those in charge of the postmenopausal health. Denosumab has shown efficacy in the control of bone loss associated with hypogonadic states created by chemotherapy in breast and other cancers. Moreover, some studies reveal efficacy in reducing the progression of metastases. A panel of experts from the Spanish Menopause Society has met to develop usage recommendations based on the best available evidence.
authors.affiliation: Hospital Universitario Dr Peset, University of Valencia, Valencia, Spain. Electronic address: Antonio.Cano@uv.es.
authors.forename: Antonio
authors.initials: A
authors.lastname: Cano
authors.affiliation: Hospital Universitario Virgen del Rocío, University of Seville, Seville, Spain. Electronic address: jsilvana@sego.es.
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Silvan
authors.affiliation: Hospital Universitario de Valme, Seville, Spain. Electronic address: antonioestevezgon@gmail.com.
authors.forename: Antonio
authors.initials: A
authors.lastname: Estévez
authors.affiliation: Hospital Vall d́Hebron, University of Barcelone, Barcelone, Spain. Electronic address: fbaromar@gmail.com.
authors.forename: Francesc
authors.initials: F
authors.lastname: Baró
authors.affiliation: Hospital Reina Sofía, Córdoba, Spain. Electronic address: jville@teleline.es.
authors.forename: José
authors.initials: J
authors.lastname: Villero
authors.affiliation: Hospital Universitario San Juan, Alicante, University Miguel Hernández, Alicante, Spain. Electronic address: fqueredas@sego.es.
authors.forename: Francisco
authors.initials: F
authors.lastname: Quereda
authors.affiliation: Hospital Universitario Central de Asturias, University of Oviedo, Spain. Electronic address: fjferrer@uniovi.es.
authors.forename: Javier
authors.initials: J
authors.lastname: Ferrer
authors.affiliation: Clinica Margen, Department of Obstetrics and Gynecology, University of Granada, Granada, Spain. Electronic address: nicomendoza@telefonica.net.
authors.forename: Nicolás
authors.initials: N
authors.lastname: Mendoza
authors.affiliation: Clínica Diatros, Barcelone, Spain. Electronic address: rschez.borrego@diatros.com.
authors.forename: Rafael
authors.initials: R
authors.lastname: Sánchez-Borrego
mesh_terms: D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000517:prevention & control / Q000556:secondary; D016723:Bone Remodeling / Q000187:drug effects; D001943:Breast Neoplasms / Q000473:pathology; D000069448:Denosumab / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D050723:Fractures, Bone / Q000191:economics / Q000517:prevention & control; D006801:Humans; D007279:Injections, Subcutaneous; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D017698:Postmenopause / Q000187:drug effects; D012449:Safety
chemical_list: D050071:Bone Density Conservation Agents; D000069448:Denosumab
keywords: Breast cancer; Denosumab; Postmenopausal osteoporosis